دورية أكاديمية
Hepatic glucokinase regulatory protein and carbohydrate response element binding protein attenuation reduce de novo lipogenesis but do not mitigate intrahepatic triglyceride accumulation in Aldob deficiency.
العنوان: | Hepatic glucokinase regulatory protein and carbohydrate response element binding protein attenuation reduce de novo lipogenesis but do not mitigate intrahepatic triglyceride accumulation in Aldob deficiency. |
---|---|
المؤلفون: | Buziau AM; Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Internal Medicine, CARIM, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands., Oosterveer MH; Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Wouters K; Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Internal Medicine, CARIM, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands., Bos T; Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands., Tolan DR; Department of Biology, Boston University, Boston, MA, USA., Agius L; Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Ford BE; Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Cassiman D; Department of Gastroenterology-Hepatology and Metabolic Center, University Hospital Leuven, Leuven, Belgium., Stehouwer CDA; Department of Internal Medicine, CARIM, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht University Medical Center+, Maastricht, the Netherlands., Schalkwijk CG; Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Internal Medicine, CARIM, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands., Brouwers MCGJ; Department of Internal Medicine, Division of Endocrinology and Metabolic Disease, Maastricht University Medical Center+, Maastricht, the Netherlands; Department of Internal Medicine, CARIM, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands; Department of Internal Medicine, CARIM, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht University Medical Center+, Maastricht, the Netherlands. Electronic address: mcgj.brouwers@mumc.nl. |
المصدر: | Molecular metabolism [Mol Metab] 2024 Sep; Vol. 87, pp. 101984. Date of Electronic Publication: 2024 Jul 06. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Elsevier GmbH Country of Publication: Germany NLM ID: 101605730 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-8778 (Electronic) Linking ISSN: 22128778 NLM ISO Abbreviation: Mol Metab Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: [München] : Elsevier GmbH, 2012- |
مواضيع طبية MeSH: | Lipogenesis* , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors*/metabolism , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors*/genetics , Liver*/metabolism , Triglycerides*/metabolism , Fructose-Bisphosphate Aldolase*/metabolism , Fructose-Bisphosphate Aldolase*/genetics , Mice, Knockout*, Animals ; Mice ; Male ; Mice, Inbred C57BL ; Adaptor Proteins, Signal Transducing/metabolism ; Adaptor Proteins, Signal Transducing/genetics ; Glucose/metabolism ; Transcription Factors/metabolism ; Transcription Factors/genetics ; Carrier Proteins |
مستخلص: | Objective: Stable isotope studies have shown that hepatic de novo lipogenesis (DNL) plays an important role in the pathogenesis of intrahepatic lipid (IHL) deposition. Furthermore, previous research has demonstrated that fructose 1-phosphate (F1P) not only serves as a substrate for DNL, but also acts as a signalling metabolite that stimulates DNL from glucose. The aim of this study was to elucidate the mediators of F1P-stimulated DNL, with special focus on two key regulators of intrahepatic glucose metabolism, i.e., glucokinase regulatory protein (GKRP) and carbohydrate response element binding protein (ChREBP). Methods: Aldolase B deficient mice (Aldob -/- ), characterized by hepatocellular F1P accumulation, enhanced DNL, and hepatic steatosis, were either crossed with GKRP deficient mice (Gckr -/- ) or treated with short hairpin RNAs directed against hepatic ChREBP. Results: Aldob -/- mice showed higher rates of de novo palmitate synthesis from glucose when compared to wildtype mice (p < 0.001). Gckr knockout reduced de novo palmitate synthesis in Aldob -/- mice (p = 0.017), without affecting the hepatic mRNA expression of enzymes involved in DNL. In contrast, hepatic ChREBP knockdown normalized the hepatic mRNA expression levels of enzymes involved in DNL and reduced fractional DNL in Aldob -/- mice (p < 0.05). Of interest, despite downregulation of DNL in response to Gckr and ChREBP attenuation, no reduction in intrahepatic triglyceride levels was observed. Conclusions: Both GKRP and ChREBP mediate F1P-stimulated DNL in aldolase B deficient mice. Further studies are needed to unravel the role of GKRP and hepatic ChREBP in regulating IHL accumulation in aldolase B deficiency. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Author(s). Published by Elsevier GmbH.. All rights reserved.) |
References: | Hepatology. 2021 Dec;74(6):3037-3055. (PMID: 34292642) Proc Natl Acad Sci U S A. 2004 May 11;101(19):7281-6. (PMID: 15118080) Gastroenterology. 2020 May;158(7):1999-2014.e1. (PMID: 32044314) Int J Environ Res Public Health. 2019 Jun 21;16(12):. (PMID: 31234281) Gastroenterology. 2014 Mar;146(3):726-35. (PMID: 24316260) PLoS Biol. 2020 Dec 4;18(12):e3000803. (PMID: 33275593) Cell Metab. 2011 Jul 6;14(1):21-32. (PMID: 21723501) Biochem J. 2008 Aug 15;414(1):1-18. (PMID: 18651836) Diabetologia. 2020 Feb;63(2):253-260. (PMID: 31713012) Cell Metab. 2006 Aug;4(2):107-10. (PMID: 16890538) J Clin Invest. 2018 Jun 1;128(6):2226-2238. (PMID: 29533924) Mol Genet Metab. 2015 Mar;114(3):445-50. (PMID: 25637246) Am J Clin Nutr. 2021 Feb 2;113(2):391-400. (PMID: 33381794) Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9116-21. (PMID: 11470916) Hepatology. 2020 Nov;72(5):1638-1653. (PMID: 32083759) Diabetes Care. 2023 Apr 1;46(4):e97-e98. (PMID: 36952606) J Clin Endocrinol Metab. 2019 Nov 1;104(11):5056-5064. (PMID: 30901028) Can J Biochem Physiol. 1959 Aug;37(8):911-7. (PMID: 13671378) J Biol Chem. 2000 Mar 17;275(11):7826-31. (PMID: 10713097) J Hepatol. 2012 Dec;57(6):1276-82. (PMID: 22878467) Hepatology. 2016 Jul;64(1):73-84. (PMID: 26707365) Diabetes Care. 2018 Feb;41(2):372-382. (PMID: 29358469) J Hepatol. 2016 Sep;65(3):589-600. (PMID: 27212244) J Biol Chem. 2021 Jan-Jun;296:100623. (PMID: 33812993) Diabetes Care. 2022 May 1;45(5):1116-1123. (PMID: 35158374) J Hepatol. 2021 Jul;75(1):46-54. (PMID: 33684506) J Clin Invest. 2020 Mar 2;130(3):1453-1460. (PMID: 31805015) Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):343-355. (PMID: 28428634) J Hepatol. 2020 Jul;73(1):202-209. (PMID: 32278004) J Chromatogr. 1983 Dec 9;278(2):231-44. (PMID: 6668307) Diabetes. 2001 Jun;50(6):1263-8. (PMID: 11375325) Hepatology. 2023 Jan 1;77(1):230-238. (PMID: 35441719) Am J Clin Nutr. 2023 Nov;118(5):1000-1009. (PMID: 37659725) Cell Mol Life Sci. 2020 May;77(9):1709-1719. (PMID: 31713637) Trends Endocrinol Metab. 2022 Oct;33(10):680-689. (PMID: 35995682) Front Endocrinol (Lausanne). 2020 Nov 17;11:594041. (PMID: 33281747) Eur J Biochem. 1989 Jan 15;179(1):179-84. (PMID: 2917560) Biochem J. 1997 Jan 1;321 ( Pt 1):239-46. (PMID: 9003425) PLoS One. 2009 Jun 26;4(6):e6066. (PMID: 19557132) J Biol Chem. 2006 Sep 29;281(39):28721-30. (PMID: 16885160) J Clin Invest. 2005 May;115(5):1343-51. (PMID: 15864352) Biochem Pharmacol. 2013 Feb 1;85(3):306-12. (PMID: 23022226) Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14511-6. (PMID: 10588736) Biochem J. 1992 Aug 15;286 ( Pt 1):253-6. (PMID: 1520277) Diabetologia. 1994 Sep;37 Suppl 2:S43-7. (PMID: 7821739) |
فهرسة مساهمة: | Keywords: Aldolase B; ChREBP; Fructose; GKRP; Glucose signalling; de novo lipogenesis |
المشرفين على المادة: | 0 (Basic Helix-Loop-Helix Leucine Zipper Transcription Factors) 0 (Mlxipl protein, mouse) 0 (Triglycerides) EC 4.1.2.13 (Fructose-Bisphosphate Aldolase) 0 (glucokinase regulatory protein) 0 (Adaptor Proteins, Signal Transducing) 0 (Gckr protein, mouse) IY9XDZ35W2 (Glucose) 0 (Transcription Factors) 0 (Carrier Proteins) |
تواريخ الأحداث: | Date Created: 20240707 Date Completed: 20240805 Latest Revision: 20240808 |
رمز التحديث: | 20240808 |
مُعرف محوري في PubMed: | PMC11300931 |
DOI: | 10.1016/j.molmet.2024.101984 |
PMID: | 38972375 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2212-8778 |
---|---|
DOI: | 10.1016/j.molmet.2024.101984 |